 |
|||||||
|
|||||||
|
|||||||
 |
|||||||
|
 |
||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|
||||||
 |
| INFANRIX Key Features |
| With INFANRIX, the DTaP in PEDIARIX, you can be consistent with how you provide protection through all five doses [1,2]. |
|
|
| - 89% efficacy in a German household contact study [4] | |
| - 84% efficacy in an Italian study sponsored by the National Institutes of Health [5] |
|
▪ After the 3-dose primary series, INFANRIX delivers sustained DTaP protection up to 6 years of age [3] |
|
|
* Efficacy is absolute protective efficacy against World Health Organization (WHO) – defined typical pertussis (≥ 21 days of paroxysmal cough and laboratory confirmation) after three doses of vaccine. |
| How is INFANRIX Supplied? |
| The following doses of INFANRIX are supplied for pediatric patients: |
|
| *See how Tip-Lok streamlines the vaccination process |
|
|
|
In clinical studies, adverse events included injection-site reactions (pain, redness, or swelling), fever and fussiness for PEDIARIX and INFANRIX, and drowsiness for INFANRIX. As with other vaccines, rare adverse events may occur. Administration with PEDIARIX was associated with higher rates of fever relative to separately administered vaccines (see Adverse Reactions section of the package insert). PEDIARIX and INFANRIX are contraindicated in people with known hypersensitivity to any component of the vaccine, including yeast, neomycin, and polymyxin B in PEDIARIX. As with any vaccine, vaccination may not protect 100% of susceptible individuals. | ||
|
|
| Related Information: Key Features Frequently Asked Questions Prescribing Information Material Safety Data Sheet Return to top |
){kind=link}